The biopharmaceutical analytical and bioanalytical contract solutions provider will invest more than US$1.7m to expand its testing capabilities
SGS is set to invest more than $1.7m to expand its North American biopharmaceutical testing capabilities at its Lincolnshire facility in the northern suburbs of Chicago, Illinois, US.
The biopharmaceutical analytical and bioanalytical contract solutions provider has announced that installation of all equipment will be completed in Q1 2019.
The site, which currently offers a wide range of analytical services, will have 313 m3 of stability storage adapted to meet the lower temperature regulatory requirements for peptides and proteins.
The investment, both in expertise and equipment, will extend the biopharmaceutical testing services offered by SGS’s current American and Canadian life science facilities.
Using state-of-the-art methodologies and instrumentation, the new services will focus on quality control analysis and stability testing of biopharmaceuticals.
This additional investment will allow SGS to offer greater capacity for GMP biologics testing capabilities in North America to better serve its biopharmaceutical clients.
“Because of its strategic geographic location, in what is a rich cluster of biopharmaceutical companies, strengthening the capabilities at the Lincolnshire laboratory will allow SGS to act as a local partner for innovators looking for expertise in biopharmaceutical analysis,” said James Nokes, VP of US Agriculture, Food and Life at SGS.
“SGS maintains its commitment to invest in its network of laboratories to offer integrated solutions and evolve for both the local and global needs of its clients.”